Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against trypanosoma cruzi infection

Journal of Infectious Diseases

Volumn 202, Issue 1, 2010, Pages 136-144

  Cazarla, Silvia I ^a,d   Frank, Fernanda M ^a   Becker, Pablo D ^d   Arnaiz, María ^b   Mirkin, Gerardo A ^a   Corral, Ricardo S ^c   Guzmán, Carlos A ^d   Malchiodi, Emilio L ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Administracion Nacional de Laboratorios E Institutos de Salud Dr Carlos G Malbran   (Argentina)

^c HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CRUZIPAIN; RECOMBINANT PROTEIN; CYSTEINE PROTEINASE; PROTOZOAL PROTEIN; PROTOZOAL VACCINE; PROTOZOON ANTIBODY;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVE SITE; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE INJURY; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS; ANIMAL; BLOOD; C3H MOUSE; CHAGAS DISEASE; ENZYMOLOGY; GENETICS; HEART MUSCLE; IMMUNOLOGY; PATHOLOGY; SKELETAL MUSCLE;

ANIMALS; ANTIBODIES, PROTOZOAN; CHAGAS DISEASE; CYSTEINE ENDOPEPTIDASES; FEMALE; MICE; MICE, INBRED C3H; MUSCLE, SKELETAL; MYOCARDIUM; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; TRYPANOSOMA CRUZI;

EID: 77953694369     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/652872     Document Type: Article

References (43)

1. Garg N, Bhatia V. Current status and future prospects for a vaccine against American trypanosomiasis. Expert Rev Vaccines 2005; 4:867-880. (Pubitemid 43040907)
2. Cazorla SI, Frank FM, Malchiodi EL. Vaccination approaches against Trypanosoma cruzi infection. Expert Rev Vaccines 2009; 8:921-935.
3. Souto-Padron T, Campetella O, Cazzulo JJ, De Souza W. Cysteine proteinase in Trypanosoma cruzi: immunocytochemical localization and involvement in parasite-host cell interaction. J Cell Sci 1990; 96: 485-1190
4. Duschak VG, Couto AS. Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. Curr Med Chem 2009; 16:3174-3202.
5. Malchiodi EL, Chiaramonte MG, Martinez JA, Zwirner NW, Margni RA, Cazzullo JJ. Identity of the major cysteine proteinase (cruzipain) from Trypanosoma cruzi and an antigen (Ag163B6) isolated with a monoclonal antibody. Immunol Lett 1993; 35:59-62.
6. Malchiodi EL, Chiaramonte MG, Taranto NJ, Zwirner NW, Margni RA. Cross reactivity studies and differential serodiagnosis of human infections caused by Trypanosoma cruzi and Leishmania spp.;use of immunoblotting and ELISA with a purified antigen (Ag 163B6). Clin Exp Immunol 1994; 97:417-423.
7. Parussini F, Duschak VG, Cazzulo JJ. Membrane-bound cysteine proteinase isoforms in different developmental stages of Trypanosoma cruzi. Cell Mol Biol 1998; 44:513-519.
8. Berasain P, Carmona C, Frangione B, Cazzulo JJ, Goñi F. Specific cleavage sites on human IgG subclasses by cruzipain, the major cysteine proteinase from Trypanosoma cruzi. Mol Biochem Parasitol 2003; 130: 23-29. (Pubitemid 37205158)
9. Frank FM, Petray PB, Cazorla SI, Muñoz MC, Corral RS, Malchiodi EL. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine 2003; 22:77-86.
10. Cazorla SI, Frank FM, Becker PD, Corral RS, Guzmán CA, Malchiodi EL. Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model. Vaccine 2008; 26:1999-2009.
11. Cazorla SI, Becker PD, Frank FM, et al. Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun 2008; 76:324-333.
12. Cazzulo JJ, Stoka V, Turk V. The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease. Curr Pharm Des 2001; 7:1143-1156.
13. CazzuloJJ,MartínezJ,ParodiAJ,WernstedtC,HellmanU. Onthepost-translationalmodificationsattheC- terminaldomainofthemajorcysteineproteinase(cruzipain)fromTrypanosomacruzi. FEMSMicrobiolLett1992;79:411-416.(Pubitemid23008552)
14. Stoka V, McKerrow JH, Cazzulo JJ, Turk V. Substrate inhibition of cruzipain is not affected by the C-terminal domain. FEBS Lett 1998; 429:129-133. (Pubitemid 28288195)
15. Huete-Pérez JA, Engel JC, Brinen LS, Mottram JC, McKerrow JH. Protease trafficking in two primitive eukaryotes is mediated by a prodomain protein motif. J Biol Chem 1999; 274: 16249-16256. (Pubitemid 129526375)
16. Del Nery E, Juliano MA, Lima AP, Scharfstein J, Juliano L. Kininogenase activity by the major cysteiny! proteinase (cruzipain) from Trypanosoma cruzi. J Biol Chem 1997; 272:25713-25718. (Pubitemid 27438889)
17. Martinez J, Campetella O, Frash AC, Cazzulo JJ. The reactivity of sera from chagasic patients against different fragments of cruzipain, the major cysteine proteinase from Trypanosoma cruzi, suggests the presence of defined antigenic and catalytic domains. Immunol Lett 1993; 35: 191-196.
18. Arnholdt AC, Piuvezam MR, Russo DM, et al. Analysis and partial epitope mapping of human T cell responses to Trypanosoma cruzi cysteiny! proteinase. J Immunol 1993;151:3171-3179.
19. Cremaschi G, Fernández MM, Gorelik G, et al. Modulatory effects on myocardial physiology induced by an anti- Trypanosoma cruzi monoclonal antibody involve recognition of major antigenic epitopes from β1-adrenergic and M2-muscarinic cholinergic receptors without requiring receptor cross-linking. J Neuroimmunol 2004; 153:99-107.
20. Ben Younès-Chennoufi A, Hontebeyrie-Joskowicz M, Tricottet V, Eisen H, Reynes M, Said G. Persistence of Trypanosoma cruzi antigens in the inflammatory lesions of chronically infected mice. Trans R Soc Trop Med Hyg 1988; 82:77-83.
21. Benítez-Hernández I, Méndez-Enríquez E, Ostoa P, et al. Proteolytic cleavage of chemokines by Trypanosoma cruzfs cruzipain inhibits chemokine functions by promoting the generation of antagonists. Immunobiology 2010; 215:413-426.
22. Tzelepis F, de Alencar BC, Penido ML, et al. Infection with Trypanosoma cruzi restricts the repertoire of parasite-specific CD8 T cells leading to immunodominance. J Immunol 2008; 180:1737-1748.
23. + T cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2006; 2:e77. doi:10.1371/journal.ppat. 0020077. Published 4 August 2006.
24. + T cells in Trypanosoma cruzi infection. Curr Opin Immunol 2009; 21:385-390.
25. + T cell responses in Trypanosoma cruzi infection. J Immunol 2009; 183:1245-1252.
26. Novotny LA, Bakaletz LO. The fourth surface-exposed region of the outer membrane protein P5-homologous adhesin of nontypable Haemophilus influenzae is an immunodominant but nonprotective decoying epitope. J Immunol 2003; 171:1978-1983.
27. Slupetzky K, Gambhira R, Culp TD, et al. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 2007; 25:2001-2010.
28. Ruckwardt TJ, Tikhonov I, Berg S, et al. Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein. J Virol 2004; 78:13190-13196. (Pubitemid 39507825)
29. Hunter CA, Ellis-Neyes LA, Slifer T, et al. IL-10 is required to preventimmune hyperactivity during infection with Trypanosoma cruzi. J Immunol 1997; 158:3311-3316.
30. Costa GC, da Costa Rocha MO, Moreira PR, et al. Functional IL-10 gene polymorphism is associated with Chagas disease cardiomyopathy. J Infect Dis 2009; 199:451-454.
31. - Th1 cells are the major source of host-protective regulatoryIL-10 during intracellular protozoan infection. J Exp Med 2007; 204:273-283.
32. Rousset F, Garcia E, Defiance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 1992; 89:1890-1893.
33. te Velde AA, de Waal Malefijt R, Huijbens RJ, de Vries JE, Figdor CG. IL-10 stimulates monocyte FcγR surface expression and cytotoxic activity: distinct regulation of antibody-dependent cellular cytotoxicity by IFN-γ, IL-4, and IL-10. J Immunol 1992; 149:4048-4052.
34. Lingnau M, Höflich C, Volk HD, Sabat R, Döcke WD. Interleukin 10 enhances the CD14-dependent phagocytosis of bacteria and apoptotic cells by human monocytes. Hum Immunol 2007; 68:730-738. (Pubitemid 47381553)
35. Mocellin S, Panelli M, Wang E, et al. IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun 2004; 5:621-630. (Pubitemid 40045300)
36. Dennis VA, Jefferson A, Singh SR, Ganapamo F, Philipp MT. Interleukin-10 anti-inflammatory response to Borrelia burgdorferi, the agent of Lyme disease: a possible role for suppressors of cytokine signaling 1 and 3. Infect Immun 2006; 74:5780-5789.
37. Rajasingh J, Bord E, Luedemann C, et al. IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression. FASEB J 2006; 20: 2112-2114.
38. Borges M, Da Silva AC, Sereno D, Ouaissi A. Peptide-based analysis of the amino acid sequence important to the immunoregulatory function of Trypanosoma cruzi Tc52 virulence factor. Immunology 2003; 109:147-155.
39. Vasconcelos JR, Hiyane MI, Marinho CR, et al. Protective immunity against Trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and transialidase. Hum Gene Ther 2004; 15:878-886.
40. +-T cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun 2005; 73:6017-6025.
41. Affranchino JL, Ibáñez CF, Luquetti AO, et al. Identification of a Trypanosoma cruzi antigen that is shed during the acute phase of Chagas disease. Mol Biochem Parasitol 1989; 34:221-228.
42. Reyes MB, Lorca M, Muñoz P, Frasch ACC. Fetal IgG specificities against Trypanosoma cruzi antigens in infected newborns. Proc Natl Acad Sci USA 1990; 87:2846-2850.
43. Prioli RP, Ortega-Barria E, Mejía JS, Pereira MEA. Mapping of a B-cell epitope in the neuraminidase of Trypanosoma cruzi. Mol Biochem Parasitol 1992; 52:85-96.